CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 51, 2008, Pages 20410-20415

  Yuan, Jianda ^a   Gnjatic, Sacha ^b   Li, Hao ^a   Powel, Sarah ^d   Gallardo, Humilidad F ^a   Ritter, Erika ^b   Ku, Geoffrey Y ^a   Jungbluth, Achim A ^b   Segal, Neil H ^a   Rasalan, Teresa S ^a   Manukian, Gregor ^a   Xu, Yinyan ^a   Roman, Ruth Ann ^d   Terzulli, Stephanie L ^a   Heywood, Melanie ^d   Pogoriler, Evelina ^d   Ritter, Gerd ^b   Old, Lloyd J ^c   Allison, James P ^a,c,d   Wolchok, Jedd D ^a,d  

^a Ludwig Center for Cancer Immunotherapy   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cytotoxic T lymphocyte associated antigen 4; Immunotherapy; Tumor therapy

Indexed keywords

ALPHA2B INTERFERON; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; GAMMA INTERFERON; IPILIMUMAB; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NY ESO 1 ANTIGEN; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MELANOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VACCINATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CYTOKINES; HUMANS; IMMUNITY; IMMUNOTHERAPY; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 58149483422     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0810114105     Document Type: Article

References (34)

1. Walunas TL, Bakker CY, Bluestone JA (1996) CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 183:2541-2550.
2. Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459-465.
3. Read S, Malmstrom V, Powrie F (2000) Cytotoxic T Lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192:295-302.
4. Salomon B, et al. (2000) B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431-440.
5. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA (1996) CTLA-4: A negative regulator of autoimmune disease. J Exp Med 184:783-788.
6. Brunner MC, et al. (1999) CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 162:5813-5820.
7. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736.
8. van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and Granulocyte/Macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-366.
9. van Elsas A, et al. (2001) Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194:481-489.
10. Hodi FS, et al. (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712-4717.
11. Phan GQ, et al. (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372-8377.
12. Hodi FS, et al. (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105:3005-3010.
13. Korman AJ, Peggs KS, Allison JP (2006) Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297-339.
14. Ribas A, et al. (2007) Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12:873-883.
15. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615-625.
16. Gnjatic S, et al. (2006) NY-ESO-1: Review of an immunogenic tumor antigen. Adv Cancer Res 95:1-30.
17. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8:247-258.
18. Precopio ML, et al. (2007) Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204:1405-1416.
19. Downey SG, et al. (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681-6688.
20. Hodi FS, et al. (2008) Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody. 2008 ASCO Annual Meeting, May 30th, Chicago USA, 3008 (abstr).
21. Maker AV, Attia P, Rosenberg SA (2005) Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175:7746-7754.
22. Comin-Anduix B, et al. (2008) Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 6:22.
23. Fong L, et al. (2008) CTLA-4 blockade for hormone refractory prostate cancer: Dose-dependent induction of CD8+ T cell activation and clinical responses. AACR, April 12th, San Diego, USA.
24. hi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 105:14987-14992.
25. Al-Batran SE, et al. (2005) Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 65:3937-3941.
26. Barrow C, et al. (2006) Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 12:764-771.
27. Duvall MG, et al. (2008) Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 38:350-363.
28. Davis ID, et al. (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proc Natl Acad Sci USA 101:10697-10702.
29. Uenaka A, et al. (2007) T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun 7:9-20.
30. Kawabata R, et al. (2007) Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int J Cancer 120:2178-2184.
31. Tsuji K, et al. (2008) Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient. Cancer Immunol Immunother 57:1429-1437.
32. Adams S, et al. (2008) Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181:776-784.
33. Valmori D, et al. (2007) Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen. Clin Immunol 122:163-172.
34. Jungbluth AA, et al. (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92:856-860.